Evidence map›Paper›PMID 37846577›Full record

ReviewCurrent stem cell research & therapy2024

Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities.

Hengameh Dortaj, Negar Azarpira, Sara Pakbaz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Hengameh DortajDepartment of Tissue Engineering and Applied Cell Science, Shiraz University of Medical Sciences, Shiraz, Iran.
Negar AzarpiraTransplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sara PakbazDepartment of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Canada.
Shiraz University · IRUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last decade, liver diseases with high mortality rates have become one of the most important health problems in the world. Organ transplantation is currently considered the most effective treatment for compensatory liver failure. An increasing number of patients and shortage of donors has led to the attention of reconstructive medicine methods researchers. The biggest challenge in the development of drugs effective in chronic liver disease is the lack of a suitable preclinical model that can mimic the microenvironment of liver problems. Organoid technology is a rapidly evolving field that enables researchers to reconstruct, evaluate, and manipulate intricate biological processes

Indexed as

LiverLiver DiseasesOrganoidsAnimalsHepatocytesHumansModels, BiologicalStem CellsTissue EngineeringhepaticLivermicrotissueorganoidsstem cells.tissue engineering

Identifiers

PMID37846577
OpenAlexW4387692640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.